Filing summary
Filing identity: The supplied filing is NeoStem, Inc.’s Form 10-Q for the quarter ended June 30, 2014, filed August 7, 2014. This conflicts with the request metadata identifying Lisata Therapeutics and 2013 Q2; verify the issuer and reporting period before relying on this summary.
Business context and reporting period
NeoStem develops cell-based therapies and operates PCT, a revenue-generating cell-therapy contract development and manufacturing business. Its programs include cancer immunotherapy, CD34-cell treatments for ischemia, T-regulatory-cell therapies, and preclinical VSEL research. Results compare the three and six months ended June 30, 2014 with the corresponding 2013 periods.
Financial performance and position
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $4.49 million | $4.36 million | $8.54 million | $6.88 million |
| Gross profit (margin) | $0.81 million (18%) | $0.12 million (3%) | $1.04 million (12%) | $0.26 million (4%) |
| Operating loss | $12.43 million | $8.17 million | $25.93 million | $17.00 million |
| Net loss | $12.77 million | $8.63 million | $26.60 million | $17.49 million |
| Net loss attributable to NeoStem common stockholders | $12.61 million | $8.58 million | $26.29 million | $17.38 million |
| Loss per share | $0.40 | $0.46 | $0.88 | $0.99 |
Revenue increased 3% in Q2 and 24% in the first half. First-half growth included higher clinical manufacturing activity and reimbursable expenses; process-development revenue can fluctuate because it is generally recognized when contracts are completed. Operating expenses rose 35% in Q2 and 44% in the first half, driven by research and development, higher corporate and acquisition-related costs, and increased share-based compensation. Per-share losses narrowed despite larger total losses, alongside a substantially higher weighted-average share count.
- Cash flow: First-half operating cash use was $22.51 million, versus $13.13 million a year earlier. Investing cash use was $3.31 million; financing provided $12.55 million. Cash and cash equivalents declined $13.27 million to $32.87 million.
- Liquidity: Cash plus marketable securities was approximately $33.79 million; working capital was approximately $28.9 million. Current assets were $40.85 million and current liabilities $11.91 million.
- Debt and other liabilities: Notes payable were approximately $1.81 million and mortgages approximately $3.13 million. Acquisition-related contingent consideration was $20.64 million at June 30, including the newly recorded CSC milestone obligation. Total liabilities were $56.10 million.
- Equity and dilution: Stockholders’ equity was $78.04 million. Common shares outstanding were 34.94 million at quarter-end and 35.25 million as of August 7, 2014. The company raised approximately $10.1 million from common-stock issuances during the first half and had $25.6 million remaining under its $30 million Aspire purchase agreement at June 30.
Material changes and significant events
- NeoStem acquired California Stem Cell, Inc. (CSC) on May 8, 2014, adding its cancer immunotherapy program and NeoStem Oncology subsidiary. The acquisition consideration included approximately 5.33 million NeoStem shares and contingent milestone payments of up to $90 million. The preliminary accounting recorded $15.0 million of goodwill and $35.8 million of in-process R&D; the final allocation remained pending.
- CSC’s NBS20/DC/TC program contributed approximately $0.01 million of revenue and a $2.3 million net loss from acquisition through June 30. The acquisition increased reported assets, liabilities, and share count; CSC’s results are included only from May 9 in reported results.
- Quarter-end cash was down from $46.13 million at December 31, 2013. Goodwill and intangible assets increased substantially, mainly from the CSC acquisition.
Outlook, management commentary, and risks
- Management expected to initiate a 250-evaluable-patient Phase 3 NBS20 melanoma trial later in 2014, with estimated trial cost of approximately $25 million. The program had FDA Fast Track and Orphan Drug designations and a Special Protocol Assessment.
- Management anticipated analysis of the completed-enrollment Phase 2 PreSERVE AMI study after collection and locking of six-month endpoint data, and expected results before its planned November 2014 scientific-session presentation. This is an expectation, not a reported result.
- Management planned 2014 Phase 2 and Phase 1 studies for Treg candidates, subject to regulatory review and approval. It noted CSC may cause reprioritization of other clinical trials.
- The company stated existing cash, revenue-generating operations, and access to the Aspire agreement were expected to fund the business as then operated into 2015. It also warned that additional capital would be needed for development, the NBS20 trial, PCT expansion, and other plans; financing may be unavailable or dilutive, and failure to raise capital could delay or curtail programs.
- Key risks include clinical-trial enrollment, outcomes and regulatory approval; uncertainty in commercializing cell therapies; reliance on external capital and strategic arrangements; acquisition integration and valuation estimates; and potential changes in contingent-consideration fair values. The company reported compliance with its mortgage liquidity covenant and no material interest-rate exposure at quarter-end.
- As a subsequent event, the company reported that August equity awards to employees for the CSC acquisition were expected to create approximately $2.4 million of compensation expense in Q3 2014.
Investor verification points
- Confirm the issuer and period: the filing is NeoStem’s Q2 2014 report, not a Lisata Therapeutics 2013 Q2 filing.
- Track cash burn, remaining Aspire financing capacity, subsequent share issuance, and whether the stated runway into 2015 remained achievable.
- Verify the NBS20 Phase 3 launch, budget, enrollment, and the timing and results of PreSERVE AMI data analysis.
- Review final CSC purchase-price allocation and changes in the $20.64 million contingent-consideration liability, including potential milestone payments.
- Assess whether service-revenue growth converts into improved gross margins and whether rising R&D and corporate costs are sustainable.